| Revenue growth | 13% YoY for FY26; 4% YoY decline for Q4FY26. |
|---|---|
| Margins | FY26 EBITDA margin up 155 bps to 19%; Gross margins stable at 44%. |
| Demand visibility | Growth across key APIs supported FY26 revenue. |
Growth
FY26 revenue grew 13% YoY to ₹887cr. Q4FY26 PAT grew 61% YoY to ₹33cr despite 4% revenue dip.
Outlook
Targeting ₹280cr capex by FY27. Aiming for 1.75x net asset turnover and high-teens returns on new capex.
Risks
Regulatory approvals at manufacturing sites; competitive generic landscape; potential raw material price fluctuations despite backward integration efforts.
Earnings Call filed with BSE, NSE: SMSPHARMA. Summary written with AI assistance from the document.
SMS Pharmaceuticals Ltd: key numbers
- Share price
- ₹475.00
- Market cap
- ₹4,211 Cr
- Revenue (annual)
- ₹886.9 Cr
- Net profit (annual)
- ₹102.0 Cr
- P/E (TTM)
- 41.1×Sector 50.4×
- Promoter holding
- 68.07%+0.00% QoQ
- FII holding
- 0.65%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from SMS Pharmaceuticals Ltd
All →SMS Pharmaceuticals Other Announcement
SMS Pharmaceuticals disclosed two market sell trades by Designated Person NVV Satyanarayana totalling ₹0.14 Crore. The PIT Reg 7(2) intimation involves a non-promoter designated person.
- Value
- ₹0.14 Cr
SMS Pharmaceuticals Annual General Meeting
SMS Pharmaceuticals Limited has scheduled its 38th Annual General Meeting for September 29, 2026. Key agenda items include dividend declaration, management re-appointments, and approval of material related party transactions.
SMS Pharmaceuticals Annual Report
SMS Pharmaceuticals Limited has released its Annual Report and Notice for the 38th Annual General Meeting scheduled for September 29, 2026. The company reported FY26 revenue of ₹887 Crore.
SMS Pharmaceuticals Credit Rating
CARE Ratings Limited has reaffirmed or revised the credit ratings for SMS Pharmaceuticals Limited's bank facilities. The review covers the company's long-term and short-term credit facilities.
SMS Pharmaceuticals Investor Presentation: Key Takeaways
SMS Pharma reported Q1FY27 revenue of ₹207 Cr (+6% YoY) with stable EBITDA margins at ~20%. Strategy focuses on high-value APIs and peptide R&D.
SMS Pharmaceuticals Q1 FY27 Results: Net Profit ₹20.9 Cr, Up 2.0% YoY
SMS Pharmaceuticals Ltd reported revenue from operations of ₹207 Cr (+5.6% YoY) and net profit of ₹20.9 Cr (+2.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹20.9 Cr · +2.0% YoY